RT Journal Article
SR Electronic
T1 Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.20.23288867
DO 10.1101/2023.04.20.23288867
A1 Jama, Maymun
A1 Zhang, Min
A1 Poile, Charlotte
A1 Nakas, Apostolos
A1 Sharkey, Annabel
A1 Dzialo, Joanna
A1 Dawson, Alan
A1 Kutywayo, Kudazyi
A1 Fennell, Dean A.
A1 Hollox, Edward J
YR 2023
UL http://medrxiv.org/content/early/2023/04/25/2023.04.20.23288867.abstract
AB Malignant pleural mesothelioma (MPM), a rare cancer a long latency period (up to 40 years) between asbestos exposure and disease presentation. The mechanisms coupling asbestos to recurrent somatic alterations are poorly defined. Gene-fusions arising through genomic instability may create novel drivers during early MPM evolution. We explored the gene fusions that occurred early in the evolutionary history. We conducted multiregional whole exome sequencing (WES) of 106 samples from 20 patients undergoing pleurectomy decortication and identified 24 clonal non-recurrent fusions, three of which were novel (FMO9P-OR2W5, GBA3 and SP9). The number of early gene fusion events detected varied from zero to eight per tumour, and presence of gene fusions was associated with clonal SCNAs involving the Hippo pathway genes and homologous recombination DNA repair genes. Fusions involved known tumour suppressors BAP1, MTAP, and LRP1B, and a clonal oncogenic fusion involving CACNA1D-ERC2, PARD3B-NT5DC2 and STAB2-NT5DC2 fusions were also identified as clonal fusions. Gene fusions events occur early during MPM evolution. Individual fusions are rare as no recurrent truncal fusions event were found. This suggests the importance of early disruption of these pathways in generating genomic rearrangements resulting in potentially oncogenic gene fusions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a British Lung Foundation-Mesothelioma UK grant MESOUK17-8. MJ was supported by a PhD studentship from the University of Leicester College of Life Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MEDUSA study was approved by NHS ethics committees under the reference 4/LO/1527 14/EM/1159.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData for figure 5 and Supplementary table 5 are available at DOI: 10.25392/leicester.data.22360534 The exome sequencing data are available from the NCBI Sequence Read Archive under accession number PRJNA649889 All other data available from the corresponding author on request. https://doi.org/10.25392/leicester.data.22360534